The relation between muscle function and muscle pain in patients with chronic myeloid leukemia (CML): a pilot study

The relation between muscle function and muscle pain in patients with chronic myeloid leukemia (CML): a pilot study - CML and muscle function

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43129

Enrollment

Registered

2017-02-09

Start date

2017-03-15

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The relation between muscle function and muscle pain in CML patients on TKIs TKI-induced myopathy

Interventions

muscle function

muscle pain

quality of life

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: age: >18 years old CML patient using any TKI (group 1 and 2) mentally able/ allowed to give informed consent

Exclusion criteria

Exclusion criteria: known hereditary muscle defect medication known to cause muscle pain (statins, antidepressiva, antipsychotica, thyroid hormones) evident prolonged QTc interval (>500 msec) contra-indication for maximal aerobic exercise test or muscle biopsy

Design outcomes

Primary

Measure	Time frame
Muscle function (= muscle force, contractile speed, relaxation, and fatigability) muscle energy metabolism (=ATP production rate, activity of mitochondrial respiratory complexes, citrate synthase activity) Cardiorespiratory fitness and anaerobic threshold (during incremental cycling test)	—

Secondary

Measure	Time frame
* Questionnaires on muscle complaints, fatigability and quality of life (short-form McGill pain questionnaire, and short-form Brief Fatigue Inventory, and short-form 36) * Blood parameters	—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)